S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
NASDAQ:VCYT

Veracyte - VCYT Stock Forecast, Price & News

$21.83
-1.41 (-6.07%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$21.81
$23.29
50-Day Range
$21.09
$27.89
52-Week Range
$14.85
$32.40
Volume
578,246 shs
Average Volume
838,253 shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.20

Veracyte MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
38.3% Upside
$30.20 Price Target
Short Interest
Bearish
5.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
0.22mentions of Veracyte in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$3.26 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.54) to ($0.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

657th out of 986 stocks

Medical Laboratories Industry

19th out of 26 stocks


VCYT stock logo

About Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Stock News Headlines

Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
Veracyte (NASDAQ:VCYT) Now Covered by StockNews.com
Veracyte to Participate in Upcoming Investor Conferences
Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
What Makes Veracyte (VCYT) a New Buy Stock
Veracyte Third Quarter 2022 Earnings: Beats Expectations
Veracyte: The FDA Is Stepping In
See More Headlines
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Company Calendar

Last Earnings
2/22/2023
Today
3/22/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCYT
Employees
761
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$30.20
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+38.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-36,560,000.00
Pretax Margin
-12.28%

Debt

Sales & Book Value

Annual Sales
$296.54 million
Book Value
$14.98 per share

Miscellaneous

Free Float
70,058,000
Market Cap
$1.58 billion
Optionable
Optionable
Beta
1.44

Social Links


Key Executives

  • Marc A. StapleyMarc A. Stapley
    Chief Executive Officer & Director
  • Rebecca ChambersRebecca Chambers
    Chief Financial Officer
  • Richard T. Kloos
    Executive Medical Director
  • Steven French
    Chief Information Officer & Senior Vice President
  • Robert Brainin
    Chief Business Officer & Executive Vice President













VCYT Stock - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VCYT shares.
View VCYT analyst ratings
or view top-rated stocks.

What is Veracyte's stock price forecast for 2023?

6 brokers have issued 12-month price objectives for Veracyte's shares. Their VCYT share price forecasts range from $22.00 to $35.00. On average, they predict the company's stock price to reach $30.20 in the next twelve months. This suggests a possible upside of 38.3% from the stock's current price.
View analysts price targets for VCYT
or view top-rated stocks among Wall Street analysts.

How have VCYT shares performed in 2023?

Veracyte's stock was trading at $23.73 at the beginning of 2023. Since then, VCYT stock has decreased by 8.0% and is now trading at $21.83.
View the best growth stocks for 2023 here
.

When is Veracyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our VCYT earnings forecast
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) issued its quarterly earnings results on Wednesday, February, 22nd. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. The biotechnology company earned $80.30 million during the quarter, compared to the consensus estimate of $74.92 million. Veracyte had a negative net margin of 12.33% and a negative trailing twelve-month return on equity of 3.42%. The firm's revenue for the quarter was up 19.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.15) earnings per share.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte updated its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $325.00 million-$335.00 million, compared to the consensus revenue estimate of $329.57 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.57%), Artisan Partners Limited Partnership (5.24%), Sumitomo Mitsui Trust Holdings Inc. (4.27%), Nikko Asset Management Americas Inc. (4.27%), ArrowMark Colorado Holdings LLC (3.89%) and Fisher Asset Management LLC (2.91%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Marc Stapley, Mark Ho and Robert S Epstein.
View institutional ownership trends
.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $21.83.

How much money does Veracyte make?

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.58 billion and generates $296.54 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How many employees does Veracyte have?

The company employs 761 workers across the globe.

Does Veracyte have any subsidiaries?
The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.
Read More
How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.

This page (NASDAQ:VCYT) was last updated on 3/23/2023 by MarketBeat.com Staff